Datapoint: Pfizer Scores Atopic Dermatitis Approval for Cibinqo

The FDA last week approved Pfizer’s JAK1 inhibitor Cibinqo for the treatment of moderate to severe atopic dermatitis in adults who have not been able to adequately manage the disease with other medications. The more limited scope of the approval is good news for Sanofi and Regeneron, whose monoclonal antibody Dupixent currently dominants the atopic dermatitis space. The drug currently holds covered or better status for 92% of all insured lives under the pharmacy benefit. 39% of lives have preferred access to Dupixent.

SOURCE: MMIT Analytics, as of 1/19/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 22

Datapoint: Highmark Launching New Primary Care Initiative in Pittsburgh

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 21

Datapoint: Novartis Asks FDA to Stave Off Early Entresto Copies

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
September 20

Datapoint: Oregon Adds Mobile Crisis Intervention to Medicaid Program

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today